Over the last five years, the number of patients we are helping has increased by nearly 50%. This has created a need to build more factories - but are there ways to do this with less environmental impact? ♻️ Come with us to our new factory site in Odense, Denmark. Here, Laila and her colleagues take some novel approaches to preserving nature and biodiversity 🌱 #NovoNordisk #DrivingChange #Sustainability
Novo Nordisk
Produktion af lægemidler
Get updates around our progress and challenges to champion long-term health 💙 #DrivingChange
Om os
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
- Websted
-
https://www.novonordisk.com
Eksternt link til Novo Nordisk
- Branche
- Produktion af lægemidler
- Virksomhedsstørrelse
- Over 10.001 medarbejdere
- Hovedkvarter
- Bagsværd
- Type
- Aktieselskab
- Grundlagt
- 1923
- Specialer
- Pharmaceuticals, Insulin, obesity, Rare Diseases og Diabetes
Beliggenheder
Medarbejdere hos Novo Nordisk
-
Thomas Røygaard
PMO | Digital Transformation | Leading Program, Project and Portfolio Management | Governance | Change Management
-
Naras Eechambadi
Board Director | Executive Coach | Global Leader in Data & AI | C-Suite Executive
-
Sören Meelby
Digital Healthcare Evangelist | Cultivating Partnerships for Collective Impact & Social Good
-
Henrik Vestergaard
Opdateringer
-
How do we create value for society? 💭 Learn more about our commitment to people living with serious chronic diseases, innovation, and access to healthcare in our #AnnualReport 2024. Experience the interactive report first-hand or download the PDF here: https://lnkd.in/dxSA_D4V
-
This International Day of Women and Girls in Science, let’s talk about why it’s important to have more women working in the field. Meet Alice Carter-Jones, our epidemiology specialist who works with big data every day to improve treatments for people living with chronic diseases. Beyond her work, she’s involved in the organisations we partner with like Women in Data®, helping to create a future where more women lead in STEM. Are you interested in pursuing your career with us? Learn about our many career paths here: https://lnkd.in/dXYGZc58 #DrivingChange #WomenInScience #STEM
-
That’s a wrap for our annual Graduate Recruitment Centre where we had the pleasure of assessing 304 talented candidates from over 50 nationalities as part of the recruitment process for the next batch of graduates 🎓 Over the past three days, these young innovators showcased their skills and teamwork while tackling a challenging business case. This event was the highlight of several months of campaigning, screening and interviews with candidates eager to join us. The overwhelming interest and the quality of the applicants in our Graduate Programme underscores the importance of our approach to attracting the right talent with an interest in driving change in long-term health globally 💙 Do you want to learn more about our Graduate Programme? Click 👉 https://lnkd.in/d3Nc2whD And don't forget to sign up for the Global Talent Hub 🌎 #novonordisk
-
-
Our full-year results for 2024 are out! Our CEO Lars Fruergaard Jørgensen breaks down some of the key highlights, including how we scaled our global production and reached more than 45 million people with our medicines. A big thanks to the more than 77,000 colleagues around the world for the dedication in bringing innovative medicine to people living with serious chronic diseases. Read more about our achievements and ambitions in our Annual Report 2024 👉 https://lnkd.in/gu4MH2U #NovoNordisk #DrivingChange #FullYearResults
-
We have just been ranked among the top 50 all-stars in Fortune's World's Most Admired Companies – and as the second most admired pharmaceutical company. These recognitions reflect our dedication to improving lives through innovation and our commitment to corporate responsibility. If you also want to make a difference and help shape the future of health, you can explore career opportunities here: https://lnkd.in/dfHdaYP #MostAdmiredCompanies
-
-
We’re proud to support 13th Avenue School in Newark, New Jersey in their mission to educate students on healthy eating habits and combat food deserts in the area. Schools are critical to driving positive change in student and community well-being. By providing education about healthy food consumption and expanding access to nutritious food across the district, schools can help address this critical need for the next generation. Chesha Hodge, MPA RDN, Director for the Coalition for Healthy Food in Newark Schools, shares more about the impactful work being done. Learn more about our commitment to serve local communities: https://bit.ly/4asP46Y #NovoNordiskUS #DrivingChange
-
Addressing our environmental impact as we grow remains a challenge, but we continue to invest in solutions to speed up our transition towards a more sustainable future. Thanks Corporate Knights for ranking us as one of the 100 Most Sustainable Corporations in the World - 2025. It is certainly work in progress, but rankings like yours help set global sustainability standards while holding us accountable to our commitment to do more with less. Curious to learn more about our actions? Read more here: https://lnkd.in/du-kF-QE #DrivingChange #Sustainability
-
We’re working with cities around the world to create healthier urban environments ⚽️🍊🚲 From cycling initiatives for children to tackling childhood obesity, here is how Cities for Better Health is making a difference. Learn more about the 2024 progress here: https://lnkd.in/djdC9V29
-
We are significantly expanding our collaboration with Valo Health to discover and develop novel treatments for cardiometabolic diseases, using large-scale human data and AI. Together, we aim to advance up to 20 drug development programs in obesity, type 2 diabetes, and cardiovascular disease. Find all details about the expanded collaboration in our press release here: https://lnkd.in/dttDY5a7 #NovoNordisk #Partnership #DrivingChange
Tilsvarende sider
Aktie
NVO
NYSE
20 minutters forsinkelse
90,58 US$
2,5 (2,838 %)
- Åbningspris
- 88,86
- Lavpunkt
- 88,12
- Højdepunkt
- 91,123
Data fra Refinitiv
Få flere oplysninger påFinansiering
Seneste runde
Post IPO-egenkapital22.000.000,00 US$